These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 16170876)
1. Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids. Cohen CJ AIDS Read; 2005 Sep; 15(9):462-5, 470-1, 474, 477. PubMed ID: 16170876 [TBL] [Abstract][Full Text] [Related]
2. Protease-inhibitor boosting in the treatment-experienced patient. Gallant JE AIDS Rev; 2004; 6(4):226-33. PubMed ID: 15700621 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. Zeldin RK; Petruschke RA J Antimicrob Chemother; 2004 Jan; 53(1):4-9. PubMed ID: 14657084 [TBL] [Abstract][Full Text] [Related]
4. Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients. Sension M; Piliero PJ J Assoc Nurses AIDS Care; 2007; 18(1):36-47. PubMed ID: 17338984 [TBL] [Abstract][Full Text] [Related]
5. Fosamprenavir calcium plus ritonavir for HIV infection. Torres HA; Arduino RC Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501 [TBL] [Abstract][Full Text] [Related]
6. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
8. Saquinavir/Ritonavir: its evolution and current treatment role. O'Brien WA AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471 [TBL] [Abstract][Full Text] [Related]
9. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B; J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902 [TBL] [Abstract][Full Text] [Related]
10. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. Youle M J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281 [TBL] [Abstract][Full Text] [Related]
11. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Tan D; Walmsley S Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450 [TBL] [Abstract][Full Text] [Related]
12. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096 [TBL] [Abstract][Full Text] [Related]
13. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. Sahali S; Chaix ML; Delfraissy JF; Ghosn J AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776 [TBL] [Abstract][Full Text] [Related]